Key facts
- Notable investors include Lapam Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Yikun Xingjian
- ·The full record, as it builds
Funding rounds
No funding rounds for Yikun Xingjian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yikun Xingjian
Developer of therapeutic drugs designed to address oncology and inflammatory diseases. The company offers small molecule immunomodulators, peptide-based drugs, and an advanced tumour-targeting delivery platform, enabling pharmaceutical researchers and healthcare providers to improve treatment precision, efficacy, and patient outcomes.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Yikun Xingjian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yikun Xingjian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yikun Xingjian in its N-PORT filings yet. We sweep new filings monthly.